Literature DB >> 21555828

Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.

Clara T M M de Kanter1, Monique Keuter, Manon J van der Lee, Peter P Koopmans, David M Burger.   

Abstract

The authors describe an HIV-infected patient with moderate renal failure receiving combination antiretroviral therapy. Because of dyslipidaemia he was initially treated with pravastatin but developed rhabdomyolysis after a switch to rosuvastatin. With this case we illustrate that statins as well as antiretroviral therapy are susceptible to clinical relevant drug-drug or drug-disease interactions. Knowledge of these interactions is important to provide patients with the best possible care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21555828     DOI: 10.3851/IMP1747

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  6 in total

Review 1.  Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.

Authors:  Benoit Chauvin; Sylvain Drouot; Aurélie Barrail-Tran; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

Review 2.  Care for Patients With Neuromuscular Disorders in the COVID-19 Pandemic Era.

Authors:  Yung-Hao Tseng; Tai-Heng Chen
Journal:  Front Neurol       Date:  2021-03-24       Impact factor: 4.003

3.  Rhabdomyolysis as Potential Late Complication Associated with COVID-19.

Authors:  Kok Hoe Chan; Jihad Slim
Journal:  Emerg Infect Dis       Date:  2020-07-02       Impact factor: 6.883

4.  Neurological manifestations in COVID-19 and its possible mechanism.

Authors:  Xiaojia Tang; Yuhan Luo; Yuxia Song; Hongyang Fan; Sisi Dong; Peipei Liu; Yingzhu Chen
Journal:  Aging (Albany NY)       Date:  2020-09-27       Impact factor: 5.955

Review 5.  What happens to cardiovascular system behind the undetectable level of HIV viremia?

Authors:  Gabriella d'Ettorre; Giancarlo Ceccarelli; Paolo Pavone; Pietro Vittozzi; Gabriella De Girolamo; Ivan Schietroma; Sara Serafino; Noemi Giustini; Vincenzo Vullo
Journal:  AIDS Res Ther       Date:  2016-04-27       Impact factor: 2.250

6.  SARS-CoV-2-associated critical ill myopathy or pure toxic myopathy?

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  Int J Infect Dis       Date:  2020-09-28       Impact factor: 3.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.